Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cistron Biotechnology(CIST)$.30 -- Ignore unavailable to you. Want to Upgrade?

To: Jonathan Rothschild who wrote (1905)	2/16/1999 11:12:00 AM
From: Walter Morton	Read Replies (2) \| Respond to of 2742

Quarterly earnings: sec.yahoo.com

To: Jonathan Rothschild who wrote (1905)	5/5/1999 12:03:00 PM
From: Steve Harmon	Respond to of 2742

$240,000 buys back 1 million shares of Cistron stock at current levels.

To: Jonathan Rothschild who wrote (1905)	5/5/1999 12:12:00 PM
From: Steve Harmon	Respond to of 2742

$480,000 buys back 2 million shares at current levels.

To: Jonathan Rothschild who wrote (1905)	5/5/1999 12:17:00 PM
From: Steve Harmon	Respond to of 2742

$720,000 buys back 3 million shares at current levels.

To: Jonathan Rothschild who wrote (1905)	5/5/1999 12:48:00 PM
From: Steve Harmon	Read Replies (1) \| Respond to of 2742

$970,000 buys back 4 million shares at current levels.

To: Jonathan Rothschild who wrote (1905)	5/6/1999 2:05:00 AM
From: Walter Morton	Respond to of 2742

So, we did not get rid of all of the board. What is your view of the new board?

To: Jonathan Rothschild who wrote (1905)	5/6/1999 9:24:00 PM
From: Steve Harmon	Respond to of 2742

Do we still have to do this? (iii) lend Mr. Galton such amount as may be required to exercise any stock options then exercisable by Mr. Galton to purchase shares of the Company's Common Stock.

To: Jonathan Rothschild who wrote (1905)	5/11/1999 11:23:00 AM
From: Steve Harmon	Respond to of 2742

From the current Genome deal orchestrated by Bruce G.>>> In addition, for acting as M&A Advisor in a Transaction, the Company shall issue GSI 400,000 warrants to purchase the Company Stock exercisable at the closing bid price on the date of the signing this agreement which will vest upon consummation of a merger or acquisition transaction. Said warrants shall have a five-year term and registration shall be the sole responsibility of the company. Question? Would you rather have those 400,000 warrants priced at .20, .30, .40, .50, .60, .70, .80, .90, or $1.00?

To: Jonathan Rothschild who wrote (1905)	5/21/1999 8:30:00 PM
From: Steve Harmon	Respond to of 2742

Was there nepotism involved here at Cistron?

To: Jonathan Rothschild who wrote (1905)	5/25/1999 7:08:00 PM
From: Steve Harmon	Read Replies (1) \| Respond to of 2742

For nearly the same $200,000 paid vacation that Bruce G. is getting>>> We could buyback nearly 1 million shares at current levels... How much longer is this fiasco going to last?

To: Jonathan Rothschild who wrote (1905)	5/27/1999 12:53:00 PM
From: scaram(o)uche	Read Replies (5) \| Respond to of 2742

Thursday May 27, 11:24 am Eastern Time Company Press Release SOURCE: Pierce Chemical Company Perstorp AB Makes Offer to Acquire Endogen, Inc. ROCKFORD, Ill., and WOBURN, Mass., May 27 /PRNewswire/ -- Perstorp AB subsidiary PerBio Science AB and Endogen, Inc. (Nasdaq: ENDG - news; BSE: EDG - news) announced today that they have executed a definitive merger agreement that provides for a cash tender offer for all of the outstanding shares of Endogen, Inc. for a total transaction value of approximately $13.6 million. PerBio Science AB, which is a leading supplier in several life science product segments, consists of the American companies Pierce Chemical Company of Rockford, Illinois; Pierce Milwaukee, Inc. of Milwaukee; and HyClone Laboratories, Inc. of Logan, Utah; and of the Sweden-based company Atos Medical. PerBio Science's offer relates to the acquisition of all of the outstanding shares of Endogen, Inc. for $3.75 per share in cash. The tender offer will be commenced within five business days. The tender offer will be conditional upon, among other things, there being validly tendered and not withdrawn at least two-thirds of the fully diluted outstanding shares of Endogen, Inc. Upon the successful completion of the tender offer, a subsidiary of PerBio Science AB will be merged into Endogen, Inc. and any Endogen, Inc. shares not tendered and purchased in the tender offer will be converted into the right to receive $3.75 per share in cash. In connection with the execution of the merger agreement, PerBio Science AB has entered into an agreement with directors and executive officers of Endogen, Inc. whereby they have agreed to tender their outstanding shares in the tender offer. As part of PerBio Science AB, Endogen, Inc. will be closely affiliated with Pierce Chemical Company. Mr. Robb Anderson, President of Pierce Chemical Company, said today, ''The merger with Endogen, Inc. will strengthen PerBio Science's position as a world leader providing biotechnology products for the rapidly growing life science research and drug discovery markets. Endogen's product portfolio adds to our existing product lines and will enable PerBio Science to expand its offerings of high-tech products for immunologists, molecular biologists and cell biologists.'' PerBio Science AB (the former Perstorp Life Science Division) is a wholly owned subsidiary of Perstorp AB, a global chemistry and materials technology corporation located in Perstorp, Sweden. In October 1999, PerBio Science AB is to be spun off to shareholders and listed on the Stockholm Exchange. Endogen, Inc. is a supplier of specialty reagents, immunoassay test kits and molecular research products to customers involved in biomedical research, the biotechnology industry and pharmaceutical drug discovery. SOURCE: Pierce Chemical Company

To: Jonathan Rothschild who wrote (1905)	6/1/1999 2:07:00 PM
From: Walter Morton	Respond to of 2742

emedtrade.com

To: Jonathan Rothschild who wrote (1905)	6/30/1999 6:10:00 PM
From: Steve Harmon	Read Replies (1) \| Respond to of 2742

JR, Cistron shareholders are in essence currently paying for 3 CEO's to manage a $5 million dollar no profit making company. This is SILLY!

To: Jonathan Rothschild who wrote (1905)	7/30/1999 1:34:00 PM
From: Walter Morton	Respond to of 2742

There are just 32 more days left before Genome Securities will refuse to accept any more acquisition/merger/collaboration proposals for Cistron Biotechnology!!! I wonder how many proposals they have to analyze before they can decide on the best proposal for the shareholders... 10, 20, 50?

To: Jonathan Rothschild who wrote (1905)	12/15/1999 1:41:00 PM
From: Chris W.	Respond to of 2742

Mr. Rothschild. I reread your post #1905 and was pleased to learn that someone from CIST cares enough about shareholders to type out a few lines. I notice you have not posted since then (feb. 99) and wonder if you could give us an update on what is going on, and your plans for CIST. I am dismayed that things have taken this long, and that so much cash has been bled from CIST for so little return, but am pleased that you seem to be a breath of fresh air for CIST. Please be an active participant of this board and keep your shareholders better informed than CIST's former officers did.